COMMUNIQUÉS West-GlobeNewswire

Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace
15/02/2019
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors and prepares for a contemplated secondary listing on the First North Stockholm marketplace Herantis [...]
MDxHealth (R): MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis
15/02/2019
NEWS RELEASE Data to be Presented at the Annual ASCO Genitourinary Cancers Symposium Data to further support clinical adoption of SelectMDx and ConfirmMDx IRVINE, CA, and HERSTAL, BELGIUM - February 15, 2019 - MDxHealth [...]
MDxHealth (R) : MDxHealth annonce la présentation des données positives de SelectMDx et de ConfirmMDx dans le diagnostic du cancer de la prostate
15/02/2019
COMMUNIQUÉ DE PRESSE Les données, visant à encourager l'adoption clinique de SelectMDx et de ConfirmMDx, seront présentées lors du symposium annuel de l'ASCO sur les cancers génito-urinaires IRVINE, CA, et HERSTAL, [...]
La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
15/02/2019
New Data on GIAPREZA™ (angiotensin II) to be Presented in Oral Sessions at the Society of Critical Care Medicine’s 48th Critical Care Congress SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company [...]
SeaSpine to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
15/02/2019
CARLSBAD, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
Lexington Biosciences Announces Termination of Private Placement
14/02/2019
VANCOUVER, British Columbia, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that, despite numerous attempts over the past 9 months, it [...]
Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial
14/02/2019
Orion Corporation Press Release Communications 14 February 2019 at 11.45 p.m. EET Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the [...]
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering
14/02/2019
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary [...]
Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
14/02/2019
SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New [...]
Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
14/02/2019
BOSTON, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
Guardant Health to Present at the 8th Annual Leerink Partners Global Healthcare Conference
14/02/2019
REDWOOD CITY, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast [...]
Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
14/02/2019
Net cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 million for the full year 2018; quarter-end cash and restricted cash position of $431.7 million provides funding to [...]
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
14/02/2019
Stockholder vote on the proposed merger with NeuBase Therapeutics anticipated in the second calendar quarter of 2019 NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or [...]
CytomX Therapeutics to Announce Full-Year 2018 Financial Results and Host Webcast Conference Call
14/02/2019
-Teleconference Scheduled for February 27, 2019, at 5:00 p.m. ET- -Company to Host Research and Development Day on February 26, 2019 in New York City- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- [...]
Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
14/02/2019
-- Trial to assess efficacy on neurodevelopmental status of MPS IIIA patients -- CAMBRIDGE, Mass. and PARIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company [...]
Achaogen Announces Proposed Public Offering of Common Stock
14/02/2019
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug [...]
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
14/02/2019
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advances Lugano, [...]
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14/02/2019
“VIVA” Trial Enrolling at Mayo Clinic SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today [...]
Rafina Innovations Begins Development on a Prototype for Sleep Apnoea
14/02/2019
GLASGOW, SCOTLAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Rafina Innovations Inc. ("the Company" (OTCQB: VICA)) is delighted to announce that it recently commenced development on a prototype for sleep [...]

Pages